ClinicalTrials.gg
RecruitingNCT05826444mCAVUpdated Aug 12, 2024

Microvascular Cardiac Allograft Vasculopathy Trial

An observational study in Cardiac Allograft Vasculopathy, sponsored by German Heart Institute. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2024-08-12.

Sponsored by German Heart Institute · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Sex
All
01

Study summary

The aim of the mCAV study is a comprehensive characterization of the genetic, morphological and functional phenotype of isolated microvascular graft vasculopathy (mCAV) after orthotopic heart transplantation (OHT).

The utilized methods include dynamic echocardiography, magnetic resonance imaging, invasive microvascular resistance measurements, histology, cellular calcium-signaling and magnetocardiography as well as molecular genetic expression analysis (miRNA based).

02

Conditions studied

  • Cardiac Allograft Vasculopathy

Keywords

  • heart transplantation
  • cardiac allograft vasculopathy
03

In context

Lead sponsor

German Heart Institute is the lead sponsor of 25 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Heart transplant recipients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • able to consent
  • Written consent of the participant after clarification and sufficient time to think about participation
  • heart transplant recipient
  • Indication for routine invasive diagnostics or due to symptoms
  • Exercise tolerant in everyday life - cycling, climbing stairs at least 2 floors at a moderate speed without symptoms of exertion or dyspnea

Exclusion criteria

Exclusion Criteria:

  • Addiction or other diseases that do not allow the patient to assess the nature and scope as well as possible consequences of the study
  • Patients or their legal guardians who do not sign the declaration of consent or who cannot fully understand it due to a lack of German language skills
  • Pregnant women, breastfeeding women
  • Severe comorbidities affecting the miRNA profile: diabetes mellitus, , end-stage renal disease with renal replacement therapy
  • to the stress test: signs of cardiac decompensation, angina pectoris, dyspnea, hyperthyroidism, \<30 ml/min, peripheral arterial disease, pheochromocytoma, angle-closure glaucoma, prostate adenoma, paroxysmal tachycardia, tachycardia atrial fibrillation
  • Evidence of an acute rejection or local wall motion disturbances in the resting echocardiography
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • microvascular cardiac allograft vasculopathy

    Heart transplant recipients with microvascular cardiac allograft vasculopathy defined by histopathology and invasive index of microvascular resistance.

    Diagnostic Test: Echocardiography · Diagnostic Test: Magnetic resonance imaging · Diagnostic Test: Magnetocardiography · Diagnostic Test: Histology · Diagnostic Test: Genetics · Diagnostic Test: calcium signaling · Diagnostic Test: IMR · Diagnostic Test: Angio-IMR

  • control

    Heart transplant recipients without microvascular cardiac allograft vasculopathy defined by histopathology and invasive index of microvascular resistance.

    Diagnostic Test: Echocardiography · Diagnostic Test: Magnetic resonance imaging · Diagnostic Test: Magnetocardiography · Diagnostic Test: Histology · Diagnostic Test: Genetics · Diagnostic Test: calcium signaling · Diagnostic Test: IMR · Diagnostic Test: Angio-IMR

Interventions

  • Diagnostic testEchocardiography

    Echocardiography with afterload change

  • Diagnostic testMagnetic resonance imaging

    Stress-MRI

  • Diagnostic testMagnetocardiography

    Magnetocardiography

  • Diagnostic testHistology

    Histological analysis

  • Diagnostic testGenetics

    miRNA sequencing

  • Diagnostic testcalcium signaling

    cardiomyocyte calcium signaling

  • Diagnostic testIMR

    Index of microvascular resistance measurement

  • Diagnostic testAngio-IMR

    Angiography derived post-processing index if microvascular resistance

06

What researchers measure

Primary outcomes

  1. mCAV status influences pw-doppler wall motion analysis in echocardiography

    pw-doppler wall motion analysis is measured with afterload increase

    Time frame: at study inclusion

  2. mCAV status influences global longitudinal strain in echocardiography

    global longitudinal strain is measured by speckle tracking analysis with afterload increase

    Time frame: at study inclusion

  3. mCAV status influences diastolic strain in echocardiography

    diastolic strain is measured by speckle tracking analysis with afterload increase

    Time frame: at study inclusion

  4. mCAV status influences cardiac deformity

    cardiac deformity analysis are performed by MRI

    Time frame: at study inclusion

  5. mCAV status influences grade of fibrosis

    fibrosis grades are measured by MRI

    Time frame: at study inclusion

  6. mCAV status influences extracellular volume

    extracellular volume is measured by MRI

    Time frame: at study inclusion

  7. mCAV status influences the circulating miRNA profile

    circulating miRNA profile is measured by miRNAseq

    Time frame: at study inclusion

Secondary outcomes

  1. mCAV status influences the intrinsic cardiac magnetic field

    the intrinsic cardiac magnetic field is measured by magnetocardiography

    Time frame: at study inclusion

  2. mCAV status influences the cellular calcium signaling

    the cellular calcium is visualized by confocal laser microscopy using electrical stimulation

    Time frame: at study inclusion

  3. mCAV status influences subcellular structures

    mitochondria, T-tubuli are described after visualization by confocal laser microscopy

    Time frame: at study inclusion

07

Study locations

1 of 1 sites recruiting
  • DHZC Deutsches Herzzentrum der Charité
    Berlin, 13353, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Dec 2025, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Apr 24, 2023
StartActual
Oct 1, 2022
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Aug 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05826444
Lead sponsor
German Heart Institute
Collaborators
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Deutsche Stiftung für Herzforschung
Responsible party
Sponsor
First posted
Apr 24, 2023
Start date
Oct 1, 2022
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Aug 12, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion